![](/sites/default/files/styles/medium/public/40yr%20old%20woman_0.jpg?itok=E43_YNKs)
New Zealand women with triple negative metastatic breast cancer may be eligible to participate in a clinical trial examining the benefits of the drug Tamoxifen to control the growth and spread of cancer cells.
About 15 per cent of all breast cancers are defined as triple negative, which means the cancer is not driven by either of the hormones oestrogen or progesterone, nor by the HER2 protein.
![Barbara](/sites/default/files/styles/medium/public/Barbara_Mason_bg_0.jpg?itok=cInHeLVX)
Breast Cancer Network is losing one of their longest standing committee members.
![](/sites/default/files/styles/medium/public/Medicines_3.jpg?itok=dJsegUzU)
New research results show that women with oestrogen receptor positive breast cancer who take the drug tamoxifen for ten years rather than five, have a reduced risk of breast cancer recurring and better overall survival rates.
The findings of the ATLAS (Adjuvant Tamoxifen – Longer Against Shorter) study were presented this week at the renowned San Antonio Breast Cancer Symposium.
![](/sites/default/files/styles/medium/public/woman%20at%20computer_3.jpg?itok=beSYqTLW)
What to do about your job while you have treatment for breast cancer can be a further stress for many women who are faced with a breast cancer diagnosis.
Many women worry about telling their employers about a diagnosis of breast cancer. And the list of concerns can be long:
A clinical trial comparing a shorter course of partial breast irradiation with standard whole breast irradiation has found that those who received the faster partial treatment were more likely to report side effects and poorer cosmetic outcomes.
New Zealand women were involved in the RAPID clinical trial which compared partial breast irradiation given twice daily over five to eight days with whole breast irradiation given daily over three to five weeks.
![](/sites/default/files/styles/medium/public/two%20women%20in%20park.jpg?itok=C9yhcSxl)
The quality of a woman’s social networks — the personal relationships that surround an individual — appear to be just as important as the size of her networks in predicting breast cancer survival, scientists report in the current issue of Breast Cancer Research and Treatment.
![](/sites/default/files/styles/medium/public/Julie%20at%20BCNA%20confernece.jpg?itok=igmG3rfk)
Breast Cancer Aotearoa Coalition committee member, Julie Graham, attended the recent Breast cancer Network Australia Strength to Strength National Conference.
![](/sites/default/files/styles/medium/public/DSC_0841.jpg?itok=GVhMTA4D)
Join fertility expert Mary Birdsall at the BCAC Annual General Meeting on November 16 2012 for a rundown on the latest in fertility options for young women with cancer.
![Adriana M.J. Bluekens, M.D.](/sites/default/files/styles/medium/public/Bluekens-lg%20for%20web.jpg?itok=a8FULXt5)
New research from the Netherlands shows that the switch from screen film mammography (SFM) to digital mammography (DM) in large, population-based breast cancer screening programs improves the detection of life-threatening cancer without significantly increasing detection of clinically insignificant disease.
![](/sites/default/files/styles/medium/public/Dove%20house%20massage%20pic.jpg?itok=TivYh2O5)
Treatment for breast cancer can be a harrowing experience for some and many women find complementary therapies can help them to survive the physical and mental challenges of treatment.
Complementary therapies include activities such as massage, meditation, acupuncture, and aromatherapy. They are not a substitute for conventional medicine, but can sometimes help women to cope better with treatment, both physically and emotionally.